Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 100 of 427 entries
View as:

Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03703375 Org: User:
Start: 11/06/18 End: 03/31/26 Due: 03/31/27

A Multiple-ascending-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT01474330 Org: User:
Start: 08/01/11 End: 10/01/11 Due: 10/01/12

A Phase 1 Trial of ABI-011 in Patients With Advanced Solid Tumors or Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT01163071 Org: User:
Start: 03/01/11 End: 09/23/11 Due: 09/23/12

Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03440385 Org: User:
Start: 03/07/18 End: 11/21/23 Due: 11/21/24

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT01358734 Org: User:
Start: 04/27/12 End: 05/15/18 Due: 05/15/19

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT03161483 Org: User:
Start: 08/31/17 End: 08/03/21 Due: 08/03/22

A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Phase: N/A Priority: Normal
NCT ID: NCT03989414 Org: User:
Start: 09/30/19 End: 11/30/26 Due: 11/30/27

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03337022 Org: User:
Start: 01/04/18 End: 04/26/19 Due: 04/26/20

Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02692339 Org: User:
Start: 02/25/16 End: 12/12/18 Due: 12/12/19

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-90006 in Healthy Subjects

Phase: N/A Priority: Normal
NCT ID: NCT02934269 Org: User:
Start: 11/21/16 End: 08/15/17 Due: 08/15/18

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00046735 Org: User:
Start: 06/01/02 End: 09/28/06 Due: 09/28/07

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT02330562 Org: User:
Start: 04/15/15 End: 06/02/21 Due: 06/02/22

A Study of CC-90011 and Comparators in Participants With Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04628988 Org: User:
Start: 07/28/21 End: 05/26/23 Due: 05/26/24

Phase III Study of ABI-007(Albumin-bound Paclitaxel) Plus Gemcitabine Versus Gemcitabine in Metastatic Adenocarcinoma of the Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT00844649 Org: User:
Start: 03/01/09 End: 04/09/13 Due: 04/09/14

Radiolabeled Study of CC-220 in Healthy Male Subjects

Phase: N/A Priority: Normal
NCT ID: NCT03294603 Org: User:
Start: 09/11/17 End: 10/16/17 Due: 10/16/18

A Study of Perpetrator Drug Interactions of Enasidenib in AML Patients

Phase: N/A Priority: Normal
NCT ID: NCT03720366 Org: User:
Start: 10/04/18 End: 12/22/23 Due: 12/22/24

A Study to Analyze the Occurrence of Transformation From Myelodysplastic Syndrome to Acute Myeloid Leukemia in Patients With Myelodysplastic Syndrome Who Received Revlimid® 5 mg Capsules and Who Are Continuing or no Longer Continuing Revlimid Treatment

Phase: N/A Priority: Normal
NCT ID: NCT02921815 Org: User:
Start: 03/03/11 End: 08/31/14 Due: 08/31/15

Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites

Phase: N/A Priority: Normal
NCT ID: NCT03665610 Org: User:
Start: 09/10/18 End: 01/10/19 Due: 01/10/20

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

Phase: N/A Priority: Normal
NCT ID: NCT02374099 Org: User:
Start: 03/13/15 End: 11/21/17 Due: 11/21/18

Safety and Pharmacologic Study of VTX-2337 in Patients With Advanced Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00688415 Org: User:
Start: 11/07/08 End: 11/30/10 Due: 11/30/11

A Phase 1 Study to Evaluate the Pharmacokinetics and Tolerability of Oral Azacitidine in Japanese Patients With Myelodysplastic Syndromes

Phase: N/A Priority: Normal
NCT ID: NCT01571648 Org: User:
Start: 04/01/12 End: 01/01/13 Due: 01/01/14

An Efficacy and Safety Study of Luspatercept (ACE-536) for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in Japanese Subjects Who Are Not Requiring Red Blood Cell Transfusion

Phase: N/A Priority: Normal
NCT ID: NCT03900715 Org: User:
Start: 05/20/19 End: 03/01/23 Due: 03/01/24

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03003520 Org: User:
Start: 02/28/17 End: 04/24/22 Due: 04/24/23

A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03906526 Org: User:
Start: 07/03/19 End: 01/24/22 Due: 01/24/23

A Phase I/II Study of ABI-007 (Abraxane®, Nab®-Paclitaxel)and Vinorelbine in Patients With Stage IV (Metastatic) Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00140140 Org: User:
Start: 08/31/05 End: 02/29/08 Due: 02/28/09